31% of European cancer indications show high benefit — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- European regulators approved 97 indications for 63 different cancer treatments from January 2022 through July 2026, but only 31% of the approved indications offered high clinical benefit.
- Nine of the 63 medicines received the top clinical-benefit grade under measurement tools used by the European Society for Medical Oncology.
- Nineteen of the 63 cancer drugs had at least one indication judged to offer high clinical benefit, while the analysis recorded 30 high-benefit indications in total.
- Five drugmakers accounted for more than half of all 30 high-benefit indications among medicines approved during the period.
- Four of the five companies were based in China or Japan; the researchers called the change a “fundamental shift in the innovation ecosystem” over the past decade.
Why it matters: European regulators approved 97 cancer-treatment indications, yet just 30 met the high-benefit threshold and five manufacturers accounted for more than half of those approvals. The high-benefit subset was therefore concentrated in a small group, including four companies based in China or Japan—a shift the researchers called fundamental to the innovation ecosystem.
Ask SkimNews
